Recent events
Recent events tied to this brand in public sources.
Back to profile81 entries · Page 1 of 5
2026
Pfizer raises full-year 2026 outlook
Pfizer raised its full-year revenue outlook to $62 billion–$64 billion from $60.5 billion–$62.5 billion, and its adjusted profit outlook to $2.95–$3.05 per share from $2.80–$3 per share.
2026
Pfizer appoints Cecile Guegan as CFO
Pfizer appointed Cecile Guegan as chief financial officer and executive vice president, effective November 1, 2026.
2026
FDA approves Talzenna plus Xtandi for HRR-mutated mHSPC
The FDA approved talazoparib (Talzenna) plus enzalutamide (Xtandi) for metastatic hormone-sensitive prostate cancer with homologous recombination repair gene mutations, expanding the combination to an earlier disease setting.
2026
Pfizer announces layoffs at North Carolina facilities
Pfizer announced a new round of layoffs affecting its Rocky Mount and Sanford facilities in North Carolina. The company did not specify the number of positions, timing, or departments affected.
2026
三生国健与辉瑞合作的PF-08634404（SSGJ-707）项目开展9项全球多中心临床试验
Sunshine Guojian's PF-08634404 (SSGJ-707) collaboration with Pfizer has launched nine global multicenter clinical trials covering non-small cell lung cancer, colorectal cancer and other solid tumor indications, with clinical development accelerating.
2023
Pfizer and Seagen receive required approvals for acquisition
Pfizer and Seagen received all required regulatory approvals to complete Pfizer's pending acquisition of Seagen. Pfizer said it expected the transaction to close on December 14, subject to customary closing conditions.
2022
Pfizer recalls quinapril-containing tablets over nitrosamine impurity
Pfizer announced a recall of six lots of Accuretic tablets and two types of quinapril and hydrochlorothiazide tablets because they contained N-nitroso-quinapril above the Acceptable Daily Intake level. The article says Pfizer was not aware of adverse events assessed to be related to the recall.
2022
Pfizer recalls Accuretic lots over excess nitrosamine
Pfizer voluntarily recalled numerous lots of Accuretic because they contained an excessive amount of nitrosamine, which increases cancer risk. The company said long-term consumption may increase cancer risk but that there was no immediate risk to patients.
2022
Pfizer recalls Accuretic and generic drug lots over nitrosamine levels
Pfizer voluntarily recalled several lots of Accuretic and two generic versions after finding nitrosamine levels above the acceptable daily intake level. The article identifies the recalled products and advises patients to consult health care providers or pharmacists.
2022
Pfizer recalls blood pressure medication lots over impurity
Pfizer said it was recalling specified lots of Accuretic and generic blood pressure medicines because of elevated levels of nitrosamine, a potentially cancer-causing impurity. The company said it was not aware of adverse events related to the recall.
2022
Pfizer recalls blood pressure medication lots
Pfizer said it was recalling six lots of Accuretic tablets and lots of two generic quinapril and hydrochlorothiazide products because of elevated levels of nitrosamine, a potentially cancer-causing impurity. The company said it was not aware of adverse events related to the recall.
2022
Alnylam files patent suits against Pfizer and Moderna
Alnylam said it separately filed suit against Pfizer and Moderna in a U.S. district court, seeking damages for alleged infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it did not plan to seek an injunction or impede vaccine production, sale, or distribution.
2022
Alnylam sues Moderna and Pfizer over lipid patent
Alnylam filed lawsuits against Moderna and Pfizer in federal court in Delaware, alleging that their COVID-19 vaccines infringe its biodegradable-lipids patent. Alnylam said it was seeking monetary relief and did not want to impede vaccine sales, production or distribution. Moderna denied the allegation; Pfizer had not commented to the outlet.
2022
Pfizer and BMS relaunch the “No Time to Wait” campaign
Pfizer and Bristol Myers Squibb relaunched the “No Time to Wait” campaign promoting Eliquis and encouraging people experiencing possible symptoms of blood clots or related conditions to seek medical attention.
2022
Pfizer sues over alleged trade-secret theft
Pfizer filed suit in the District of Connecticut against former employees Xiayang Qiu and Min Zhong and others. The complaint alleges that Qiu and Zhong stole Pfizer trade secrets and confidential information and later incorporated them into Regor; these are allegations in the complaint.
2022
Pfizer and Beam Therapeutics announce research collaboration
Pfizer announced a four-year exclusive research collaboration with Beam Therapeutics focused on in vivo base-editing programs for rare genetic diseases. The reported terms include an upfront payment to Beam and potential milestone payments.
2022
FDA approves Cibinqo for atopic dermatitis
The FDA approved Cibinqo for treating patients with moderate to severe atopic dermatitis.
2021
FDA approves Xeljanz for ankylosing spondylitis
Pfizer said the U.S. FDA approved the supplemental New Drug Application for Xeljanz (tofacitinib) to treat adults with active ankylosing spondylitis who had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
2021
FDA clears Pfizer COVID-19 booster for ages 16 and 17
The FDA cleared the Pfizer COVID-19 booster for 16- and 17-year-olds, permitting teenagers in those age groups to receive a third dose at least six months after their initial series.
2021
AWS announces arrangements with Pfizer and Rivian
AWS announced new arrangements involving Pfizer and Rivian. Pfizer described plans to use AWS capabilities through a new Pfizer Amazon Collaboration Team initiative; Rivian chose AWS as its preferred cloud provider.